GSA Capital Partners LLP Increases Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

GSA Capital Partners LLP raised its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,658 shares of the company's stock after buying an additional 37,275 shares during the period. GSA Capital Partners LLP owned about 0.08% of Centessa Pharmaceuticals worth $1,498,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of CNTA. Acadian Asset Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at about $330,000. Platinum Investment Management Ltd. boosted its position in Centessa Pharmaceuticals by 27.3% during the first quarter. Platinum Investment Management Ltd. now owns 485,174 shares of the company's stock worth $5,482,000 after acquiring an additional 104,091 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth about $109,000. Affinity Asset Advisors LLC boosted its position in Centessa Pharmaceuticals by 4.4% during the first quarter. Affinity Asset Advisors LLC now owns 830,546 shares of the company's stock worth $9,385,000 after acquiring an additional 34,817 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company's stock worth $33,427,000 after acquiring an additional 418,615 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. BMO Capital Markets boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. Jefferies Financial Group boosted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a "buy" rating and a $33.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $25.17.

Centessa Pharmaceuticals Trading Down 3.0 %

Shares of Centessa Pharmaceuticals stock traded down $0.54 on Thursday, reaching $17.54. The company had a trading volume of 270,136 shares, compared to its average volume of 401,747. The firm's 50 day moving average price is $15.81 and its two-hundred day moving average price is $12.03. The firm has a market cap of $1.99 billion, a PE ratio of -11.82 and a beta of 1.47. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Saurabh Saha sold 4,169 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now owns 827,755 shares in the company, valued at $10,197,941.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now owns 223,369 shares in the company, valued at approximately $3,350,535. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 4,169 shares of the company's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the transaction, the chief executive officer now owns 827,755 shares of the company's stock, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 325,031 shares of company stock valued at $5,213,043 in the last ninety days. Company insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.